Givinostat is an ‘HDAC inhibitor’ in that it blocks enzymes called histone deacetylases (HDACs), which are involved in turning genes ‘on’ and ‘off’ within cells and can reduce muscle regeneration in Duchenne. By inhibiting HDAC activity givionostat may help to activate muscle repair mechanisms to increase muscle fiber regeneration, reduce inflammation, and reduce fibrosis.
A Phase 3 study in Duchenne has been completed. A Phase 2 study in Becker has been completed.
This program is sponsored by Italfarmaco SpA.
JUNE 2021 | Italfarmaco Presents at the PPMD 2021 Virtual Annual ConferencePre-recorded content for PPMD's 2021 Virtual Annual Conference On-Demand Library |
APRIL 2020 | Webinar: Italfarmaco Provides Givinostat UpdateItalfarmaco joined PPMD for a webinar on April 22, 2020 to update the community about Italfarmaco’s development of Givinostat and the recent results of the futility analysis of the enrolling Phase 3 confirmatory study in Duchenne muscular dystrophy. |
JUNE 2019 | Italfarmaco Presents at the PPMD 2019 Annual Conference |
MARCH 2019 | Webinar: Italfarmaco Provides Givinostat UpdateItalfarmaco joined PPMD for a webinar on March 27, 2019 to update the community about Italfarmaco's development of Givinostat and the enrolling Phase 3 confirmatory study in Duchenne muscular dystrophy. |
JUNE 2018 | Italfarmaco Presents at the PPMD 2018 Annual Conference |
JAN 2018 | Webinar: Italfarmaco Provides Givinostat UpdateItalfarmaco joined PPMD for a webinar on January 24, 2018 to update the Duchenne community about Italfarmaco's development of Givinostat and the enrolling Phase 3 confirmatory study in Duchenne muscular dystrophy. |
APRIL 2017 | Webinar: Givinostat in DuchenneParent Project Muscular Dystrophy and Italfarmaco hosted a webinar on April 26, 2017 to discuss Italfarmaco's investigational drug Givinostat (a histone deacetylase (HDAC) inhibitor) and how it works in Duchenne. Our speakers presented a brief history of the development program, including pre-clinical results and preliminary results of the current Phase 2 clinical trial, study 43, which is ongoing in Italy, and answered questions from our community. |
